AI

TetraScience resolves root cause scientific data problems with a cloud-native platform, purpose-built to benefit scientists and data scientists, who use Tetra Data for automation and ML/AI. This paid-for advertorial by TetraScience appeared in the DDW / SLAS supplement in DDW Volume 23, Issue 1 – Winter 2021/22  Technology drives the value of scientific inquiry and outcomes. There continues to be brilliant […]

Sanofi and Exscientia have announced a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples.   Background  The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation […]

Machine learning (ML) holds the promise to revolutionise drug discovery. By integrating vast datasets into predictive models, ML will help researchers arrive at the optimal candidate compounds more quickly, disrupting the long cycle times of preclinical discovery research. DEL technology is unmatched in its ability to produce ultra-large datasets. By harnessing the power of next-generation […]

Listen to this article on the DDW Podcast:   The workload in pharmacovigilance (PV) is soaring and as new vaccines and medications enter the market, it’s crucial to track adverse events (AE). As AE reports still have to be filed within 24 hours, Kathleen O’Brien of Amplexor Life Sciences lays out a blueprint for centralising global AE reporting.  AE notifications come in […]

TARA Biosystems, a biotechnology company using human biology and data for cardiac drug discovery, has collaborated with Scipher Medicine, a precision medicine company. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies.   Cardiac laminopathies, associated with mutations in the LMNA gene, can result in electrical and mechanical changes in the heart. These […]

Listen to this article on the DDW Podcast:   Panna Sharma is the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics. Lu Rahman spoke to the man behind this biotech to find out why he believes AI is about to […]

The life sciences data landscape is growing in complexity and scale, with organisations generating increasingly high volumes of data. Yet, these data are still stored and searched using outdated methods. As a result, there are vast amounts of unstructured data stored in various siloed locations. Vladimir Makarov, Consultant at Pistoia Alliance, discusses this challenge and […]

Artificial intelligence (AI) is intelligence demonstrated by machines, as opposed to intelligence demonstrated by animals (including humans). According to a report by IDTechEx, the application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. They say the potential for AI to address these pain […]

Exscientia, the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences has published final results from the EXALT-1 trial in Cancer Discovery.  The study, titled “Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional Responders,” illustrates the potential real-world impact of using Exscientia’s AI-supported precision medicine platform (referred to in […]

BenevolentAI has idenitifed a preclinical candidate for a novel ulcerative colitis target. It is in IND/CTA-enabling studies and the company plans to advance it to move the programme into the clinic in early 2023. Scientists deployed BenevolentAI’s target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature […]

Valo Health is a technology company built to transform drug discovery and development using human-centric data and artificial intelligence-powered compute. VP of Integrated Research, Guido Lanza talks to DDW in its Drug Discovery 2021 supplement about how Valo Health is re-inventing and innovating to overcome the fragmented, outdated drug discovery and development process that exists today.  According […]

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development. Jeff Elton, CEO of ConcertAI, who has extensive experience in this sector, shares his insight with DDW. There has been a recent flurry of news at […]

Artificial Intelligence (AI) is the simulation of human intelligence processes by machines, particularly computer systems, and finds itself at a climactic moment for its use within the drug discovery industry, especially as the world emerges from the Covid-19 pandemic.   “Artificial intelligence and machine learning continue to play important roles in drug discovery”, said Rupert Vessey, […]

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development says Jeff Elton, CEO of Concerto HealthAI, who has extensive experience in this sector, and shares his insight with DDW.  In the full interview, which can be downloaded and […]

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his career and the future of […]

IBM Research and Arctoris are investigating the application of AI and automation to accelerate closed loop molecule discovery.   IBM Research has developed RXN for Chemistry, an online platform leveraging Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is designed to perform reaction predictions […]